Abstract
Objective: Automated voxel-based analysis methods are used to detect cortical hypometabolism typical of Alzheimer’s Disease (AD) on FDG-PET brain scans. We compared the accuracy of two clinically validated tools for their ability to identify those MCI subjects progressing to AD at followup, to evaluate the impact of the analysis method on FDG-PET diagnostic performance.
Methods: SPMGrid and BRASS (Hermes Medical Solutions, Stockholm, Sweden) were tested on 131 MCI and elderly healthy controls from the EADC PET dataset. The concordance between the tools was tested by correlating the quantitative parameters (z- and t-values), calculated by the two software tools, and by measuring the topographical overlap of the abnormal regions (Dice score). Three independent expert readers blindly assigned a diagnosis based on the two map sets. We used conversion to AD dementia as the gold standard.
Results: The t-map and z-map calculated with SPMGrid and BRASS, respectively, showed a good correlation (R > .50) for the majority of individual cases (128/131) and for the majority of selected regions of interest (ROIs) (98/116). The overlap of the hypometabolic patterns from the two tools was, however, poor (Dice score .36). The diagnostic performance was comparable, with BRASS showing significantly higher sensitivity (.82 versus .59) and SPMGrid showing higher specificity (.87 versus .52).
Conclusion: Despite similar diagnostic performance in predicting conversion to AD in MCI subjects, the two tools showed significant differences, and the maps provided by the tools showed limited overlap. These results underline the urgency for standardization across FDG-PET analysis methods for their use in clinical practice.
Keywords: FDG-PET, Alzheimer's disease, MCI, Automated analysis, tatistical parametric mapping, hypometabolic pattern.
Current Alzheimer Research
Title:A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment
Volume: 17 Issue: 13
Author(s): Valentina Garibotto*, Sara Trombella, Luigi Antelmi, Paolo Bosco, Alberto Redolfi, Claire Tabouret-Viaud, Olivier Rager, Gabriel Gold, Panteleimon Giannakopoulos, Silvia Morbelli, Flavio Nobili, Robert Perneczky, Mira Didic, Eric Guedj, Alexander Drzezga, Rik Ossenkoppele, Bart Van Berckel, Osman Ratib and Giovanni B. Frisoni
Affiliation:
- Laboratory of Neuroimaging and Innovative Molecular Tracer, University of Geneva, Geneva,Switzerland
Keywords: FDG-PET, Alzheimer's disease, MCI, Automated analysis, tatistical parametric mapping, hypometabolic pattern.
Abstract:
Objective: Automated voxel-based analysis methods are used to detect cortical hypometabolism typical of Alzheimer’s Disease (AD) on FDG-PET brain scans. We compared the accuracy of two clinically validated tools for their ability to identify those MCI subjects progressing to AD at followup, to evaluate the impact of the analysis method on FDG-PET diagnostic performance.
Methods: SPMGrid and BRASS (Hermes Medical Solutions, Stockholm, Sweden) were tested on 131 MCI and elderly healthy controls from the EADC PET dataset. The concordance between the tools was tested by correlating the quantitative parameters (z- and t-values), calculated by the two software tools, and by measuring the topographical overlap of the abnormal regions (Dice score). Three independent expert readers blindly assigned a diagnosis based on the two map sets. We used conversion to AD dementia as the gold standard.
Results: The t-map and z-map calculated with SPMGrid and BRASS, respectively, showed a good correlation (R > .50) for the majority of individual cases (128/131) and for the majority of selected regions of interest (ROIs) (98/116). The overlap of the hypometabolic patterns from the two tools was, however, poor (Dice score .36). The diagnostic performance was comparable, with BRASS showing significantly higher sensitivity (.82 versus .59) and SPMGrid showing higher specificity (.87 versus .52).
Conclusion: Despite similar diagnostic performance in predicting conversion to AD in MCI subjects, the two tools showed significant differences, and the maps provided by the tools showed limited overlap. These results underline the urgency for standardization across FDG-PET analysis methods for their use in clinical practice.
Export Options
About this article
Cite this article as:
Garibotto Valentina*, Trombella Sara , Antelmi Luigi, Bosco Paolo , Redolfi Alberto, Tabouret-Viaud Claire , Rager Olivier, Gold Gabriel , Giannakopoulos Panteleimon , Morbelli Silvia , Nobili Flavio , Perneczky Robert , Didic Mira , Guedj Eric , Drzezga Alexander , Ossenkoppele Rik , Berckel Van Bart , Ratib Osman and Frisoni B. Giovanni , A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment, Current Alzheimer Research 2020; 17 (13) . https://dx.doi.org/10.2174/1567205018666210212162443
DOI https://dx.doi.org/10.2174/1567205018666210212162443 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Aberrant Neuronal Activity and Dysfunctional Connectivity in Aβ<sub>1–42</sub>- mediated Memory Deficits in Rats
Current Alzheimer Research Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Cushing's Syndrome and Steroid Dementia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Paying Attention to Pharmacokinetic and Pharmacodynamic Mechanisms to Progress in the Area of Anticholinergic Use in Geriatric Patients
Current Drug Metabolism Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications
Current Medicinal Chemistry The Impact of Working Memory Training on Cognitive Abilities in Older Adults: The Role of Cognitive Reserve
Current Aging Science Novel Biosynthesis, Metabolism and Physiological Functions of L-Homoarginine
Current Protein & Peptide Science Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis
CNS & Neurological Disorders - Drug Targets Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research Preface [Hot Topic: Current Trends in the Development of Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents (Executive Editors: P. Camps and D. Munoz-Torrero)]
Current Pharmaceutical Design Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Cholinesterase Inhibition of Selected 4-Methylcoumarins in Comparison to their Antioxidant Activity
Current Bioactive Compounds Lipid Nanoformulations in the Treatment of Neuropsychiatric Diseases: An Approach to Overcome the Blood Brain Barrier
Current Drug Metabolism Novel Detection System for Plant Protein Production of Pharmaceuticals and Impact on Conformational Diseases
Protein & Peptide Letters Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued)